SEC Form 4 · accession 0001209191-15-033448
Foundation Medicine, Inc. · FMI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
David P Schenkein
Director
Period of report
Apr 7, 2015
Accepted (ET)
Apr 9, 2015 · 5:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001488613
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 7, 2015 | U | 25,218 | $50.00 | D | 6,032 | D | |
| Common StockF1,F2 | Apr 7, 2015 | U | 25,218 | $50.00 | D | 6,032 | I | David P. Schenkein 2004 Revocable Trust |
| Common StockF1,F3 | Apr 7, 2015 | U | 25,218 | $50.00 | D | 6,032 | I | Amy P. Schenkein 2004 Revocable Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The amount reported represents the estimated number of shares sold by the reporting person in connection with the tender offer for shares of Common Stock of the Issuer (the "Tender Offer") by Roche Holdings, Inc. ("Roche"). Roche will purchase only a prorated portion of the shares properly tendered by each tendering stockholder. Based on a preliminary count reported by Roche, the preliminary proration factor for the Tender Offer is approximately 80.7%. If necessary, an amended Form 4 will be filed to report the number of shares actually sold by the reporting person in connection with the Tender Offer once the final proration factor is determined.
- F2These shares are held in a trust for the benefit of the Reporting Person. The Reporting Person is trustee of the trust.
- F3These shares are held in a trust for the benefit of the Reporting Person's spouse. The Reporting Person is trustee of the trust.